Computational Pathology Market Report Scope & Overview:

The computational pathology market size was valued at USD 648.30 million in 2024 and is expected to reach USD 1251.72 million by 2032, growing at a CAGR of 8.62% over the forecast period of 2025-2032.

The global computational pathology market is being driven by the rapidly evolving therapeutic landscape and the growing utility of AI, digital imaging, and machine learning tools in diagnostic pathology. These methods improve precision, decrease turnaround times, and benefit clinical decision making. Increasing prevalence of chronic diseases, increasing use of digital pathology for pharmaceuticals, and growing digitization in healthcare also ensure a growing market. Moreover, strategic partnerships of hospitals and AI startups are driving innovation, placing computational pathology at the forefront of precision medicine.

To Get more information on Computational Pathology Market - Request Free Sample Report

The U.S. computational pathology market size was valued at USD 197.89 million in 2024 and is expected to reach USD 372.18 million by 2032, growing at a CAGR of 8.26% over the forecast period of 2025-2032.

The U.S. is a leading country in the North American computational pathology market, which is a result of the well-established health care infrastructure, early adoption of AI technologies, and substantial investments in digital pathology. Strong regulatory backing and the players of highest influence further establish the U.S. as the leader in such a market.

Market Dynamics:

Drivers

• Rising Incorporation of AI and Machine Learning in Diagnostics is Boosting the Market Growth

Artificial intelligence (AI) and machine learning (ML) in pathology are key computational pathology market growth factors as these technologies significantly improve the accuracy, speed, and consistency of diagnostics. Machine learning models can be "trained" to identify traits in pathology slides—such as tumor margins, cell structure, or biomarker expression—that are challenging for the human eye to resolve consistently. AI models are also able to go through an enormous amount of digital images much faster than a traditional manual review, enabling more laboratory efficiency and the ability of pathologists to spend more time on difficult cases. With a growing trust in the clinical value of AI-powered applications, there is a propensity for hospitals and research institutions to adopt computational pathology in their diagnostic processes.

The University of Pittsburgh’s Computational Pathology and AI Centre (CPAU) in a USD 10million, five-year commitment with Leidos to deploy AI tools, including generative models, to accelerate the accuracy of leukemia diagnosis for underserved populations.

University of Cambridge coeliac AIUniversity of Cambridge coeliac AI tool.

Researchers created an AI model using more than 4,000 histological slides that can diagnose coeliac disease in less than a minute, far reducing the time required by pathologists to review them, which ranges from around 5 to 10 minutes per slide.

• Escalating Demand for Digital Transformation of Healthcare Systems is Augmenting the Market Growth

The more general digitalization of healthcare – a response to the demands for efficiency, correctness, and consolidation of data – is driving the adoption of computational pathology. Several health care systems have shifted their practice of analog microscopy to DS scanning and cloud-based systems, facilitating real-time access to images, remote consultation, and efficient case management. This shift is being driven in part by favorable government regulations and funding initiatives promoting the modernization of hospital IT infrastructure. Digital solutions offer opportunities to better integrate pathology data within electronic health records (EHRs) and other diagnostic services, enabling more holistic and data-driven patient care. With the rapid growth in digital health ecosystems, computational pathology stands to play a central role in the future of diagnostics.

Queensland Government’s pathology funding, from a USD 6.9 million investment, allowed several hospitals in Queensland were able to implement digital slide scanners to improve remote diagnostics and reduce turnaround times by around 30%

In 2024, Philips advanced its cloud-based digital pathology collaboration with AWS to enhance the platform’s scalability, data security, and application within healthcare systems.

Restraint

• Data Privacy and Regulatory Challenges are the Restraining Factors for the Virtual Data Room Software Market

Data privacy and regulatory concerns are some of the key factors hampering the growth of the computational pathology market. Computational pathology depends on large amounts of digital patient data, such as high-resolution pathology slides and clinical records, all of which are regulated by healthcare data protection laws such as HIPAA (U.S.), GDPR (Europe), or other local frameworks.

While a variety of AI tools and cloud platforms are used to analyze and centralize this data, the healthcare providers grapple with complex issues related to data encryption, secure access, and anonymization. A breach or failure to comply can result in serious legal penalties and damage to reputation and patient confidence. In addition, the regulatory approval of computational pathology tools is very different in different parts of the globe, which makes it difficult to implement them cross-border. Together, these barriers decelerate the uptake of digital technology in clinical settings, especially in well-regulated contexts.

Segmentation Analysis:

By Component

The software segment dominated the computational pathology market share in 2024, with a 68.2% as AI-enabled platforms, machine learning algorithms, and image analysis tools are largely integrated in the diagnostic workflow. Such software applications help pathologists interpret complex slides of digital pathology in large volumes with improved accuracy, consistency, and speed. Their capacity for automating cell counting, tumor identification, analysis, and pattern recognition has, in particular, decreased human errors and facilitated more accurate diagnostics. Increasing usage of whole-slide imaging and cloud-based analytics further established the software as a central catalyst for computational pathology.

The services are anticipated to grow at the highest CAGR in the forecast years, due to the rising demand for cloud support, managed services, system integration, and training. With hospitals and research facilities ordering complex digital pathology systems, the need for tailor-made solutions for infrastructure maintenance, customization of AI models, and round-the-clock technical support is increasing. Meanwhile, alliances between healthcare providers and tech companies are driving consulting, deployment, and data management services, also boosting growth in the segment.

By Application

The disease diagnosis segment dominated the computational pathology market share in the year 2024 with a 46.15% owing to a rising use of digital pathology in the diagnostic pathway in a clinical environment, enabling to enhancement of the accuracy, speed, and consistency of a diagnosis. AI-based image analysis software plays a major role in cancer detection, biomarker discovery, and clinical decision support. The incorporation of computational pathology into everyday diagnostics enables pathologists to cope with increasing case numbers and maintain the accuracy of results. The application segment is led by the disease diagnosis segment, as the market is driven by the need to carry out disease diagnosis rapidly and in an efficient manner, especially in the fields of oncology and chronic disease management.

The academic research segment is likely to hold the fastest-growing market during the forecast period due to increasing collaborative research among universities, healthcare providers, and AI companies. As computational pathology becomes increasingly sophisticated, academic institutions are using these tools to investigate new biomarkers, disease mechanisms, and advanced diagnostics. Moreover, growing support for research funding in the medical field and growing adoption of digital platforms for education and experimentation are contributing to the swift adoption of computational pathology tools in academic institutions.

By Technology

The machine learning segment dominated the computational pathology market share in 2024 as it can analyse complex imaging data efficiently, detect patterns, and improve diagnostic quality. ML belongs to the canonical methods in pathology; examples include cell classification, tumor recognition, and tissue microstructure segmentation. They learn more and more as they analyze large data sets, and they can help pathologists make more accurate and reproducible decisions. ML, with its flexibility, potential, and scalability, became a core backbone for most, if not all, AI-based diagnostic tools being used in the clinic and for research.

Natural Language Processing (NLP) Models segment is anticipated to be the fastest growing segment during the forecast period, as there is a compelling requirement for extracting meaningful insights from unstructured pathology reports, clinical notes, and research literature. NLP allows the retrieval of text-based data, which can be combined with imaging findings, thereby improving the interpretability of patient files and decision support. As the health data becomes increasingly complex, NLP methods are being adopted in computational pathology, especially in the research and translational medicine settings, where the gap between raw data and knowledge that can be acted on exists.

By End Use

The hospitals and diagnostic labs segment dominated the computational pathology market with a 68.14% in 2024, owing to the rising need for effective, precise, and scalable diagnosis in the clinical setting. Such organizations are now opting for digital pathology platforms combined with artificial intelligence (AI) and machine learning solutions to manage a large number of pathology slides, minimize diagnostic errors, and expedite turnaround. The adoption of WSI and automated solutions in the hospital and laboratory has greatly enhanced operational productivity and patient treatment results, cementing this segment’s dominance within the market.

The biotechnology and pharmaceutical companies segment will exhibit the highest growth in the forecast period due as computational pathology is crucial for drug discovery, transnational research, and biomarker production. These include using AI-driven pathology platforms to analyze tissue samples with greater precision during trials and to speed the process of developing targeted therapies. In an age where the pharmaceutical industry is moving more and more toward precision medicine, the demand for high-throughput, data-driven pathology tools is growing, making this segment a critical area of future market growth.

Regional Analysis:

North America dominated the computational pathology market with a 40.10% market share in 2024, due to the increase in its healthcare infrastructure with the technology prior, and also independent and individualistic usage of digital technology, backed by the FDA. The area also has the presence of a critical mass of market players, large research laboratories, and huge investments in precision medicine and healthcare digitalization. Meanwhile, tech companies are partnering with medical institutions, thus facilitating faster integration of AI-based pathology solutions in diagnostic labs and hospitals.

Asia Pacific is anticipated to be the fastest-growing region in the computational pathology market with 9.17% CAGR over the forecast period, with increasing healthcare spending, growing patient awareness about digital health, and rising burden of chronic diseases. The companies are seeing a growing demand for AI and machine learning tools in pathology across countries such as China, India, and Japan, driven primarily by increasing government funding, better healthcare facilities in these regions, and the presence of local digital health startups. Its high patient volume and extensive initiatives to improve healthcare facilities also add to the fast development of the region.

The computational pathology market trends in Europe are growing at a significant CAGR due to the advanced healthcare infrastructure, rising usage of diagnostic solutions based on AI technology, and focus on personalized medicine. Germany, the UK, and France, along with a number of other countries, are at the forefront of this evolution, spurred on by supportive government policy and increasing demand for digital health services. The progress in the region is also supported by, for instance, the EU Cancer Plan and Horizon Europe that will promote innovation, integration of digital technologies in health care, etc. The power of the relationships between healthcare providers, researchers, and technology companies is helping put Europe on the map as a new hotbed for computational pathology adoption.

The moderate growth of the computational pathology market trends in Latin America and the Middle East & Africa (MEA) is increasing. In Latin America, this surge is powered by the growing penetration rate of AI-based diagnostic solutions, particularly in the space of oncology, and growing awareness of digital health solutions. Pathology processes are slowly being modernized by governments and private healthcare in countries such as Brazil and Mexico.

In the MEA, the computational pathology market analysis is witnessing significant growth due to the continued healthcare digitization initiatives and increasing demand for effective diagnostic solutions. Though the rate of adoption is disparate from one country to the next, there is a growing need for advanced pathology solutions in modern, urban medical centers and in academic settings. As healthcare infrastructure develops and precision diagnostics garner interest, both regions are projected to remain growing.

Get Customized Report as per Your Business Requirement - Enquiry Now

Key Players:

The computational pathology market companies are Koninklijke Philips N.V., F. Hoffmann‑La Roche Ltd., PathAI, Inc., Hamamatsu Photonics K.K., Olympus Corporation, Visiopharm A/S, Mikroscan Technologies, Inc., MindPeak GmbH, Indica Labs, LLC, Nucleai, Inc., Proscia Inc., Ibex Medical Analytics Ltd., 3DHISTECH Ltd., Leica Biosystems, Apollo Enterprise Imaging Corp., Applied Spectral Imaging (ASI), Quibim, Owkin, Genedata, Aiforia Technologies, and other players.

Recent Developments:

• April 29, 2025 – Roche reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This is the first time a computational pathology companion diagnostic (CDx) device has been granted such designation, highlighting its innovative potential in precision diagnostics.

• June 2025 – PathAI, a leading provider of AI-powered pathology solutions, has entered into a multi-year strategic collaboration with Northwestern Medicine, Chicago’s leading integrated academic health system. As part of the partnership, Northwestern Medicine will deploy PathAI’s AISight digital pathology image management system to enhance diagnostic efficiency and quality in pathology workflows.

• March 2023 – During the USCAP 112th Annual Meeting, which took place from March 11–16 at the Ernest N. Morial Convention Center, Agilent Technologies Inc. unveiled an end-to-end digital pathology solution. The platform combines Agilent's technologies with Visiopharm, Proscia, and Hamamatsu technologies in an effort to offer a best-in-class digital pathology solution for both clinical and research use.